Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nebivolol Education Efforts Will Tout Performance In Hypertension Subgroups

Executive Summary

Forest has already started conducting postmarketing studies for its antihypertensive nebivolol - in advance of the product's approval - "to further highlight potential differences from existing beta blockers," according to Investor Relations VP Charles Triano

You may also be interested in...



Forest Hopes Efficacy In Blacks And Tolerability Will Set Bystolic Apart

With approval of Forest/Mylan's Bystolic (nebivolol) - the newest member of a crowded beta blocker class - the company is gearing up to launch with an experienced sales force, data to differentiate the drug, and a price in line with one of the most commonly used drugs in the class

Forest Hopes Efficacy In Blacks And Tolerability Will Set Bystolic Apart

With approval of Forest/Mylan's Bystolic (nebivolol) - the newest member of a crowded beta blocker class - the company is gearing up to launch with an experienced sales force, data to differentiate the drug, and a price in line with one of the most commonly used drugs in the class

Drug Reimbursement In Brief From Pharma Earnings Calls

Formulary access for Lipitor: "Our access remains in the range of 65 to 70 [percent] at tier 2 across commercial and Medicare lives," Pfizer Worldwide Pharmaceutical Operations President Ian Read commented during the firm's third quarter earnings call Oct. 18. Noting that U.S. prescriptions for the cholesterol reducer were down about 13 percent compared to 2006, he pointed out that losses from patient switches to generics have "stabilized" and the product's new patient volume is "fluctuating at around a 20 percent share." Lipitor's third quarter revenues declined 3 percent to $3.2 billion versus the comparable 2006 quarter...

Related Content

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel